Re: ZEN-3694 mCRPC Trial Status
in response to
by
posted on
Oct 26, 2017 10:24AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Nextblockbuster
Yep, this has the potential to yield SanFran's Star Factories each being sold or licensed (possibly numerous regions and/or companies). Even with just a few "Stars" this could generate huge revenue. With a current set of 1500 compounds there potentially could be many stars.
Zenith shareholders (of which there were 125,207,692 shares issued) own a private company called Zenith Capital which owns the royalty preferred shares of RVX and it owns 100% of Zenith Epigenetics. I haven't checked the shareholder structure lately but I believe Eastern is dominant by far and Don has management control at this stage.
The question I possed before, and I'd like to hear from experts on this, is how will share holders ever receive a payout on their shares. For example, let's say ZenEpi sells a "Star" and generates $2,000,000,000 as an example. This money could stay within ZenEpi or it could flow to ZCC to fund acquisitions and other trials, etc. Either way the money sits in 1 of 2 private companies. So what are the options for me to get money for my shares?
Anyway, this is not at all clear to me. I sure like to hear some POVs because I know from the past 9 years Don is not going to treat shareholders like me very well at all.
GLTA
Toinv